Nuplazid suppresses esophageal squamous cell carcinoma growth in vitro and in vivo by targeting PAK4

Background Due to the high recurrence and low 5-year survival rates of esophageal squamous cell carcinoma (ESCC) after treatment, the discovery of novel drugs for recurrence chemoprevention is of particular importance. Methods We screened the FDA-approved drug library and found that Nuplazid, an atypical antipsychotic that acts as an effective 5-HT 2 A receptor inverse agonist, could potentially exert anticancer effects in vitro and in vivo on ESCC. Results Pull-down results indicated that Nuplazid binds with p21-activated kinase 4 (PAK4), and a kinase assay showed that Nuplazid strongly suppressed PAK4 kinase activity. Moreover, Nuplazid exhibited inhibitory effects on ESCC in vivo. Conclusions Our findings indicate that Nuplazid can suppress ESCC progression through targeting PAK4.


BACKGROUND
Esophageal cancer is the seventh most commonly diagnosed cancer and the sixth most common cause of cancer-related mortality worldwide [1]. Esophageal squamous cell carcinoma (ESCC) accounts for~90% of esophageal cancers [2], and is typically treated with surgery, chemotherapy, radiotherapy and combination therapy [3,4]. However, even with treatment, the 5-year overall survival rate has been reported to be~47%, with 49% of patients developing locoregional progression or distant progression [5,6]. Therefore, it is important to identify novel drugs with low toxicity and high efficacy to prevent the recurrence of ESCC and increase the survival rate of patients. The repositioning of drugs can overcome the challenges of high wastage, high cost, and time-consuming drug development [7,8]. Screening drugs approved by the FDA and repositioning their anti-tumour effects have the potential to overcome several challenges associated with drug development and to guarantee rapid clinical trials. p21-Activated kinase 4 (PAK4) is involved in numerous signaling pathways and plays a pivotal role in cytoskeleton regulation, cell migration, growth, proliferation and survival [9]. The overexpression of PAK4 is reported to be closely related to the occurrence and development of various cancers, including pancreatic [10], breast [11,12], ovarian [13], and gastric cancers [14]. Currently, several compounds have been identified as PAK4 inhibitors, which typically target the ATP-binding pocket of PAK4 kinase domain [15]. However, the transition from compound inhibitors to clinical medications needs to overcome time-consuming and exorbitant cost factors.
Nuplazid, an atypical antipsychotic that functions as an effective 5-HT 2 A receptor inverse agonist, is mainly used to treat Parkinson's disease psychosis [16]. In this study, we screened drugs approved by the FDA and found Nuplazid could inhibit the growth of ESCC in vitro. Then our study found that Nuplazid treatment inhibits the growth of ESCC by binding to PAK4 and regulating its downstream signaling pathway interaction. The anticancer effects of Nuplazid on ESCC in vitro and in vivo suggested Nuplazid might be a candidate for ESCC chemoprevention.

Cell culture
The Shantou human embryonic esophageal (SHEE) cell line was obtained from Dr. Enmin Li (Medical College of Shantou University) [17]. Human esophageal cancer cell lines KYSE150, KYSE410 and KYSE450 cells were purchased from the Type Culture Collection of the Chinese Academy of Science. ESCC cells were cultured in RPMI-1640 medium (Biological Industries, China) supplemented with 10% inactivated FBS (Biological Industries, China) and 1% penicillin/streptomycin. The cells were cytogenetically tested by STR-Promega and were authenticated (August, 2014 and July, 2017) [18,19]. HEK293T cells (ATCC) were cultured in DMEM medium (Biological Industries, China). All cells were maintained at 37°C in a humidified 5% CO 2 incubator.

Cytotoxicity assay and cell proliferation assay
Cells (SHEE, KYSE150 and KYSE450; 8 × 10 3 /well) were seeded in 96-well plates with 0.1 ml of medium containing 10% FBS. After incubation for 16 h, 0.1 ml, a medium with different concentrations of Nuplazid was added. After incubation for another 24 h and 48 h for cytotoxicity assay and 24, 48, 72 and 96 h for cell proliferation assay, the plates were removed from the incubator. Hundred microlitres of 1 μg/ml DAPI was added to each well after fixing the cells with 4% paraformaldehyde for 30 min. After incubation at 37°C for 20 min, the cells were counted by a high content imaging system (In Cell Analyzer 6000, GE Healthcare).

Anchorage-independent cell growth
The soft-agar colony formation assay was used to determine the anchorage-independent cell growth. Three millilitres Eagle Basal Medium with 10% FBS and 0.6% agar was added to each well of a six-well plate and solidified at room temperature for 2 h. ESCC cells (8 × 10 3 /well) were suspended in 1 ml Eagle's Basal Medium (BME) with 10% FBS and 0.3% agar and subsequently plated over the solidified bottom layer. After incubation at 37°C in 5% CO 2 for 7 days, the colonies were photographed and counted using a high content imaging system (In Cell Analyzer 6000, GE Healthcare).

Plate clone formation assay
Cells (200/well) were seeded in six-well plates with 2 ml of medium containing 10% FBS. After 16 h incubation, 2 ml of medium with different concentrations of Nuplazid was added to each well. After incubation for 7 days, the plates were removed from the incubator and the clones were stained with 0.5% crystal violet for 15 min after fixation with 4% paraformaldehyde for 30 min. Then the clones were photographed and counted.
Cell sample preparation and Phosphoproteome analysis KYSE150 (4.5 × 10 6 cells) were seeded into a 15 cm dish and treated with 5 μM Nuplazid or DMSO for 24 h as control. For trypsin digestion, protein was extracted from cells using buffer with 8 M urea with 1% protease inhibitor cocktail. After reduction with 5 mM dithiothreitol at 56°C for 30 min, the protein sample was alkylated with 11 mM iodoacetamide for 15 min RT in darkness. Then 100 mM TEAB was added to dilute samples to a urea concentration less than 2 M. Trypsin was added to the sample (according to mass ratio 1:50 trypsin-toprotein) for the first digestion overnight and 1:100 trypsin-to-protein mass ratio for a second 4 h digestion. After digestion with trypsin, peptide was desalted by Strata X C18 SPE column (Phenomenex) and vacuum-dried according to the manufacturer's protocol for TMT kit/ iTRAQ kit. After reconstitution in 0.5 M TEAB and processing by TMT kit/ iTRAQ kit (Thermo, 90064), peptides were fractionated by high pH reverse-phase HPLC using Agilent 300Extend C18 column (5 μm particles, 4.6 mm ID, 250 mm length). The peptides were subjected to NSI source followed by tandem mass spectrometry (MS/MS) in Q ExactiveTM Plus (Thermo) coupled online to the UPLC.

Data analysis
The resulting MS/MS data were processed using Maxquant search engine (v.1.5.2.8). The results were exported into Excel to facilitate database research. KEGG pathway research was conducted to analyse quantitative protein and phosphorylation sites. P < 0.05 was evaluated for statistical significance. FDR was set to <1%.

Knockdown of PAK4 by shRNA
The shRNA against human PAK4 was inserted into the pLKO.1 vector. Human shPAK4 full hairpin sequence is #2 CGAGAATGTGGTG GAGATGTA, #5 CGACCAGCACGAGCAGAAGTT. HEK293T cells were transiently transfected with pLKO.1 or shPAK4 plus pMD2.G and psPAX2. The cells were placed in fresh medium after 4 h. Then the lentivirus enriched culture medium was collected at 24 and 48 h post-transfection and stored at −80°C until required for use. The KYSE150 and KYSE450 cells were seeded and infected with lentivirus medium supplemented with polybrene (8 µg/mL; YESEN). After 48 h, the infected cells were selected in complete growth medium supplemented with 2 μg/mL of puromycin (Solarbio) for 24-48 h.

Immunoprecipitation
KYSE150 and KYSE450 (2 × 10 6 cells) were seeded into a 10 cm dish and treated with 5 μM nuplazid or DMSO for 24 h as control. Cell pellets were incubated with lysis buffer (50 mM Tris-HCl pH 8.0, 0.5% NP40, 150 mM NaCl) for 30 min at 4°C. After quantification, appropriate cell lysates were incubated with 40 μL of protein A/G agarose beads and rotated for 2 h at 4°C. Then collect cell lysate and add PAK4 antibody, 40 μL of protein A/G agarose beads was then added to each sample and rotated overnight at 4°C. The beads were washed four times with lysis buffer, and the immune complexes were eluted at 95°C for 5 min with 6×loading buffer. The immunoprecipitated complexes were then separated by SDS/PAGE and subjected to western blot analysis.

Pull-down assay
Nuplazid-conjugated Sepharose 4 B beads or Sepharose 4 B beads were incubated with PAK4 protein or cell lysates (500 µg) in reaction buffer (2 mg/mL BSA, 50 mM Tris-HCl pH 7.4, 200 mM NaCl, 5 mM EDTA, 1 mM dithiothreitol, and 0.01% NP40) at 4°C overnight. After the beads were washed three times by wash buffer (200 mM NaCl, 50 mM Tris pH 7.4, 5 mM EDTA, 0.01% NP40, and 1 mM dithiothreitol), the proteins were eluted from the beads through boiling in loading buffer at 95°C for 5 min. Protein binding was then assessed using Western blotting.

Western blot analysis
Cells were seeded into a 15 cm dish at 4.5 × 10 6 cells/well and treated with Nuplazid for 24 h. Total protein was extracted from cells using RIPA lysate buffer. Protein samples (30 μg, quantified by the BCA Protein Assay Kit) were boiled with loading buffer at 98°C for 8 min and then were subjected to SDS-PAGE and transferred to a PVDF membrane (Immobilon®-P Membrane). After blocking with 5% non-fat milk for 1 h at room temperature, the membrane was incubated with primary antibody at 4°C overnight. The next day, the membrane was incubated with the corresponding secondary antibody at room temperature for 2 h after being washed three times with TBST. Protein bands were visualised using the enhanced chemiluminescence (ECL, Meilunbio®).

In vitro kinase assay
The activity of PAK4 was determined in a kinase reaction buffer with 200 μM ATP, in the presence of the kinase (100 ng of His-PAK4) and 200 ng of the substrate (His-MAPK1) at 30°C for 30 min. The reaction was stopped by adding sample loading buffer and heating at 100°C for 5 min. The kinase activity was visualised by detecting the indicated antibodies with -western blotting.

Computational modeling of PAK4 with Nuplazid
For in silico docking of Nuplazid and PAK4, we used the Maestro 11.5 software program. To model the binding of Nuplazid with PAK4, the crystal structure of PAK4 (PDB number 2cdz) was downloaded from the PDB database (www. rcsb.org/pdb [PDB]). And water molecules in the structure were removed and hydrogen atoms were added to the protein prior to docking. The structure of Nuplazid was downloaded from PubChem database (https://pubchem.ncbi. nlm.nih.gov/) for the docking study. The PyMOL program was used to prepare the Nuplazid for the docking study.

Colony numbers (200 cells/well
Institutional Animal Care and Use Committee (CUHCI2019002, CUHCI2021001, and CUHCI2021005). SCID-CB17 mice were purchased from Charles River and kept under specific pathogen-free conditions. ESCC tissues were obtained from the First Affiliated Hospital of Zhengzhou University, and written informed consent for the use of the tissue samples was provided by all patients. ESCC fragments of~1-2 mm 3 were seeded under the skin of the mice. Mice were randomly divided into three groups of eight animals each as follows: (1) untreated vehicle group; (2) 11 mg Nuplazid/kg of body weight and (3) 44 mg Nuplazid/kg body weight. Mice were given Nuplazid or vehicle (10% DMSO in 0.9% saline) by gavage every day. Tumour volume was calculated by the following formula: tumour volume (mm 3 ) = (length × width 2 )/2. When the tumour volume reached~1000 mm 3 , the mice were anesthetised, and the tumour weight was measured.

Immunohistochemistry analysis
After fixation with 4% formaldehyde for at least 48 h, tumour tissues were embedded in paraffin blocks and subjected to immunohistochemistry (IHC). Serial 4 μm paraffin tissue sections were rehydrated using alcohol and TBST after being deparaffinised at 60°C for 2 h. Next, the slides were boiled in sodium citrate buffer solution for 15 min. Afterwards, the tissue sections were treated with 3% H 2 O 2 for 8 min. For IHC, tissues were hybridised with the Ki67 and p-MAPK1 T185/Y187 primary antibody (1:50) at 4°C overnight. Then the slides were incubated with HRP-IgG secondary antibody after being washed with TBST. Finally, the slides were stained with diaminobenzidine (DAB) for 2 min and then counterstained with hematoxylin. All sections were scanned using Tissue Faxes (TissueGnostics, version 4.2) and the Image Pro Plus software program (Media Cybernetics, Rockville, MD) was used to calculate positive cells.

Statistical analysis
All quantitative results are expressed as mean values ± SD from three times replicates. SPSS 21.0 was applied to evaluate significant difference. Oneway ANOVA or a non-parametric test was used for statistical analysis; p < 0.05 was considered statistically significant.

Nuplazid inhibited the proliferation of ESCC cells
To select a drug that can effectively suppress ESCC proliferation, we screened an FDA-approved drug library with a toxicity assay. We found Nuplazid (compound number 22) exhibited toxic effects on KYSE450 cells (Fig. 1a). The specific information of the compound is in Table 1 of the Supplementary data. Nuplazid is a 5-HT 2 A receptor inverse agonist (Fig. 1b) that is mainly used to treat Parkinson's disease. The IC50 of Nuplazid on ESCC cells and immortalised epithelial cells was evaluated by a cell cytotoxicity assay. The results indicated that Nuplazid exhibited more toxic effects on KYSE150 and KYSE450 cells compared to SHEE cells ( Fig. 1c and Fig. S1). To determine the inhibitory effect of Nuplazid on ESCC, KYSE150 and KYSE450 cells were treated with Nuplazid (0, 0.5, 1, 2.5 and 5 µM). The results indicated that Nuplazid effectively suppressed the growth of ESCC cells in a dose-dependent manner (Fig. 1d, e). We next investigated whether Nuplazid could inhibit anchorage-independent growth of ESCC cells. The soft-agar assay showed that Nuplazid could significantly block the anchorage-independent growth of KYSE150 and KYSE450 cells in a dose-dependent manner (Fig. 1f). In addition, the growth inhibitory effect of Nuplazid on ESCC was  evaluated. The results of the plate clone formation assay also indicated that clone formation in KYSE150 and KYSE450 cells was inhibited after Nuplazid treatment (Fig. 1g). Together, these results indicate that Nuplazid inhibits ESCC cell growth in vitro.
Nuplazid affects PAK4/MAPK1 signaling To investigate the anticancer mechanism of Nuplazid in ESCC cells, KYSE150 cells were treated with 5 μM Nuplazid or DMSO for 24 h as a control. Subsequently, we analysed proteomic and phosphorylation changes after Nuplazid treatment by performing mass spectrometry. The quality control report indicated that this test was in line with the standards (Fig. S2A and B). According to proteomic and phosphoproteomic analysis, 5165 proteins were quantified from 6449 proteins, and 5988 phosphorylation sites were quantified from 8852 sites. To evaluate statistical significance, strict criteria (t-test P-value < 0.05, FDR < 0.01) were applied to three biological replicates. Among all the quantified phosphosites, we discovered that 572 phosphosites were changed by 283 sites up and 289 sites down according to P-value < 0.05 (fold change > 1.5 or fold change < 0.67) (Fig. 2a). A series of phosphosites were differentially expressed in KYSE150 cells after Nuplazid treatment (Fig. 2b). The quantified phosphorylation sites were mapped to the KEGG signaling pathway, and the top five signaling pathways are shown in a KEGG pathway enrichment map (Fig. 2c). Based on the dataset, all changed phosphorylation sites are determined and the phosphorylation site of MAPK1 at 187 was a visible downregulated site (Figs. 2d and S2C). Western blot analysis revealed that the level of p-MAPK Y187 was decreased in KYSE150 and KYSE450 cells treated with Nuplazid for 24 h (Fig. 2e). To identify the upstream kinases that regulate these proteins, the upstream kinase was predicted based on changes in protein phosphorylation sites, which showed that the kinase activity of PAK4 may be regulated by Nuplazid (Fig. S3). Meanwhile, Swiss Target also predicted PAK4 may be the target protein of Nuplazid (Fig. S3). We found that PAK4 and MAPK1 were positively correlated by TCGA database analysis (Fig. S3). Therefore, we hypothesised that Nuplazid may target PAK4 and regulate its downstream signaling pathway.

Nuplazid inhibited the kinase activity of PAK4
To identify whether Nuplazid could regulate the kinase activity of PAK4, we used a recombinant active PAK4 protein and inactive MAPK1 protein to perform an in vitro kinase assay. The results   verified that Nuplazid could suppress the phosphorylation of MAPK1 (Fig. 4a). Because Nuplazid inhibited PAK4 kinase activity and could bind with PAK4 at ATP-binding sites ASP444, we performed pull-down assays with ATP to investigate how Nuplazid interacts directly with PAK4 kinase. The binding of Nuplazid to PAK4 decreased in the presence of ATP (Fig. 4b), indicating that Nuplazid suppresses the kinase activity of PAK4 by an ATPcompetitive manner. We next determined whether the PAK4 downstream signaling in ESCC cells could be affected by Nuplazid. After treatment with Nuplazid for 24 h, the proteins in KYSE150 and KYSE450 cells were extracted and PAK4 signaling pathway molecules were detected by Western blotting. Results indicated Nuplazid inhibited MAPK1 phosphorylation in a dose-dependent manner, whereas PAK4 and phosphorylated PAK4 remained unchanged (Fig. 4c, d). To further determine whether Nuplazid could affect PAK4 interact with MAPK1, KYSE150 cells and KYSE450 cells treated with Nuplazid. PAK4 was used to immunoprecipitate MAPK1 and p-MAPK1 T185/Y187 was used to detect p-MAPK1 T185/Y187 by Western blot analysis. The results indicated that PAK4 can combine with MAPK1 and Nuplazid could decreased the level of p-MAPK1 T185/Y187 through affected the kinase activity of PAK4 (Fig. 4e, f).

Nuplazid suppressed ESCC growth through PAK4
To investigate whether PAK4 knockdown might mediate the growth of ESCC, we established multiple PAK4 knockdown cell lines. Western blotting results showed that the expression of PAK4 in cells transfected with two individual PAK4 shRNA was significantly decreased compared with control cells (Fig. 5a). And the level of p-MAPK1 T185/Y187 was decreased in PAK4 knockdown cells (Fig. 5a). Then we used cell proliferation and anchorage-independent cell growth assays to assess whether the knockdown of PAK4 inhibits the growth of ESCC. Cells with PAK4 knockdown exhibited slower growth and colony formation compared to control sh-mock cells (Fig. 5b, c). To further provide PAK4 plays an active role in ESCC, we assessed whether overexpression of PAK4 could promote cell proliferation in ESCC cells. First, we detected the expression levels of PAK4 in different ESCC cell lines, and the results showed that PAK4 was lowly expressed in KYSE410 cells (Fig. S4). Then we established PAK4 overexpressing KYSE410 cells. The Western blot result showed that the expression of PAK4 in KYSE410 cells was significantly higher than control cells that expressed the empty PLVX-IRES-puro vector (Fig. 5d) and the level of p-MAPK1 T185/Y187 was increased in PAK4 overexpressing cells (Fig. 5d). As expected, overexpression of  All data are shown as means ± S.D. The asterisks (*, **, ***) indicate a significant decrease (p < 0.05, p < 0.01, p < 0.001, respectively).
PAK4 significantly promoted the cell growth (Fig. 5e) and colony formation (Fig. 5f) compared to control cells. Taken together, these data demonstrated that the PAK4 play an important role in ESCC cells.
To verify whether Nuplazid affects the proliferation of esophageal cancer cells through PAK4, shPAK4-KYSE150, shPAK4-KYSE450 cells and their control sh-mock cells were treated with 2.5 μM Nuplazid. The results indicated the growth of cells with PAK4 knockdown was less inhibited compared to control sh-mock cells (Fig. 5g). In summary, Nuplazid inhibits ESCC growth through PAK4.

Nuplazid suppressed ESCC PDX tumour growth in vivo
To examine the anti-tumour activity of Nuplazid against the growth of ESCC tissues in vivo, ESCC PDXs models were established in mice. To determine the dose of Nuplazid for the in vivo experiment, we performed a potential toxicity profile of Nuplazid. Based on the daily oral dose in humans, mice were administered Nuplazid at 11 mg/kg or 44 mg/kg every day by gavage for 2 weeks. The results indicated that there was no body weight change in mice between the Nuplazid-treated group (11 mg/kg or 44 mg/kg) and the vehicle-treated group (Fig. S5). Therefore, mice were administered Nuplazid at either 11 mg/kg or 44 mg/kg daily by gavage over a period of 30 days. The results indicated that the Nuplazid treatment significantly suppressed tumour growth compared with the vehicle-treated group (Fig. 6a,  b). Moreover, tumour weight was significantly decreased in the Nuplazid 44 mg/kg treatment group compared with the vehicletreated group (Fig. 6c). Meanwhile, the results indicated that although the tumour in the vehicle-treated group grew rapidly, Nuplazid reduced the growth of most tumours (Fig. 6d). Next the   Fig. 6 Nuplazid inhibits the growth of esophageal cancer patient-derived xenograft tumours in vivo. a The photograph showed tumour tissues from PDX mice treated with solvent or Nuplazid (11 mg/kg or 44 mg/kg). b Tumour volumes were measured every 3 days. c After sacrificing, isolated tumours were weighted. d Data recorded tumour size of individual mice. Immunohistochemistry analysed the level of ki67 (e) and p-MAPK1 T185/Y187 (f) in tumour tissues from treated or untreated groups of mice. All data are shown as means ± S.D. The asterisks (*, **, ***) indicate a significant decrease (p < 0.05, p < 0.01, p < 0.001, respectively).
effect of Nuplazid on the expression of Ki67 was investigated by IHC, and the results indicated that the Nuplazid treatment significantly inhibited the expression of Ki67 in tissues compared with the vehicle-treated group (Fig. 6e). The effect of Nuplazid on the PAK4 signaling pathway in tumour tissues was examined, and the results indicated that the Nuplazid treatment strongly suppressed the phosphorylation of MAPK1 in LEG110 tumours (Fig. 6f).

DISCUSSION
Esophageal cancer is one of the most common malignant tumours, with an estimated 572,000 new cases and 509,000 deaths annually [20]. Despite recent advances in treatments, patient prognosis remains poor [21][22][23]. Therefore, it is urgent to identify effective agents for ESCC prevention or recurrence prevention [24]. Drug repurposing has the potential to overcome several challenges associated with de novo drug discovery and guarantees quick clinical trials due to the already-established pharmacokinetics, tolerability, safety, and toxicity profile of the drug. Therefore, screening the FDA-approved drug library to select lowtoxicity and high-efficiency drugs for cancer prevention or recurrence prevention is extremely attractive. Through this strategy we discovered that Nuplazid was cytotoxic against ESCC cells and that it suppressed ESCC proliferation and clone formation in vitro. Nuplazid is an effective 5-HT 2 A receptor inverse agonist that is clinically used to treat Parkinson's disease psychosis [25]. Recently, a study reported that Nuplazid exerts anticancer effects in pancreatic cancer cells [26]. However, the molecular targets and the inhibitory mechanism of Nuplazid remain to be elucidated.
Here, by analyzing phosphoproteome data after Nuplazid treatment and predicting the upstream kinase of the protein mapped to the signal pathway, we found that the activity of PAK4 changed significantly. Moreover, Swiss target analysis indicated that Nuplazid binds with PAK4. Interestingly, the binding assays and in vitro kinase assay provided strong evidence that Nuplazid targeted PAK4 and inhibited its activity. Interestingly, we found that MAPK1 can be phosphorylated by PAK4 at Y187, which was proved by in vitro kinase assay. MAPK1 Y187 levels can be suppressed by Nuplazid treatment. All together, the PAK4 signaling pathway in ESCC cells was inhibited after Nuplazid treatment.
Accumulated evidence supports a critical role for abnormal PAK4 expression in oncogenesis, and amplification or activation of PAK4 has been detected in numerous cancers [27][28][29], including pancreatic, breast, and ovarian cancers [30]. Recent studies have indicated that PAK4 is associated with the risk of ESCC, and TCGA database analysis indicated that PAK4 expression in ESCC tissues was higher than in normal tissues [31]. We found that knockdown of PAK4 significantly suppressed the growth of ESCC cells, and knockdown of PAK4 led to ESCC cell resistance to Nuplazid. These multiple pieces of evidence indicated that PAK4 is a promising target of ESCC.
Fluorouracil, capecitabine, oxaliplatin and paclitaxel are often used in combination as chemotherapeutic agents for ESCC [32][33][34][35][36]. However, these drugs have side effects on the patient's physical and mental state, and the gradual development of drug resistance is also a challenge for clinical treatment [37]. Recently, studies have reported that some PAK4 molecular inhibitors, LCH-7749944 [15], FRAX1036 [38], and GNE 2861 [39], showed inhibitory effects in melanoma cells, colon cancer cells, breast cancer cells, and gastric cancer cells. However, these PAK4 inhibitors are still in preclinical research. Thus, a new PAK4 inhibitor that is not inferior in efficacy but that is favourable in toxicity is urgently needed. Nuplazid is a clinical drug already approved by the FDA with established safety data. Importantly, in the in vivo experiment, we proved that Nuplazid significantly suppressed tumour growth in mice PDXs at its clinical dose, which paved its way for further clinical trials.
In conclusion, our findings support the idea that Nuplazid is a potent PAK4 inhibitor, and could be used in ESCC chemoprevention.